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Introduction {#sec1}
============

Natural killer (NK) cells are innate lymphoid cells able to discriminate and eliminate infected cells and tumor cells because of a large panel of germline-encoded receptors ([@bib4], [@bib27]). The stimulatory receptor NKp46 is one of the natural cytotoxic receptors (NCRs) expressed on all NK cells ([@bib37]). It efficiently triggers the release of cytotoxic granules, cytokines, and chemokines upon binding ligands of viral ([@bib29]), bacterial ([@bib49]), and cellular origin ([@bib34]) in addition to unidentified ligands on tumor cells ([@bib5]). Human NKp46 and its mouse ortholog NKp46/NCR1 (CD335) ([@bib3]) are immunoglobulin (Ig)-like transmembrane glycoproteins. In addition to NK cells, NKp46 is also expressed by type 1 innate lymphoid cells (ILC1s) ([@bib6], [@bib60]), a subset of group 3 ILCs ([@bib32]) and a small subset of T cells. NKp46-deficient mice (*Ncr1*^*gfp/gfp*^) have been widely used to demonstrate the importance of NKp46 in the control of microbial infection ([@bib14]) and tumor development by NK cells ([@bib15]) as well as in contributing to type 1 diabetes ([@bib18]).

When activated, NK cell lytic activity is mainly mediated via exocytosis of cytotoxic granules containing a payload predominantly made up of perforin and granzymes. Other pathways include the engagement of death receptors via membrane-bound or soluble proteins that belong to the tumor necrosis factor (TNF) family of cytokines ([@bib13]). The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) is a type II transmembrane protein ([@bib55]) constitutively expressed on liver-resident NK cells in humans ([@bib44]) and in mice ([@bib35], [@bib46], [@bib56]), a population of cells that has recently been categorized as ILC1s ([@bib6], [@bib24]). In addition to TRAIL, the transcription factors T-bet and Eomesodermin (Eomes) are commonly used to identify resident NK cells in the mouse ([@bib9], [@bib17]) and human liver tissue ([@bib8], [@bib20]). Other markers include chemokine receptors ([@bib44]) and integrins of the CD49 antigen-like family ([@bib2], [@bib9], [@bib17]), showing similarities between mouse- and human-resident NK cells described in healthy livers ([@bib30]). These tissue-resident ILC1s have recently been shown to represent a major early source of interferon γ (IFN-γ), making them important first responders to viral infection ([@bib53])

Human and mouse TRAIL engage receptors that possess a death domain and induce caspase 8-mediated apoptosis, including TRAIL-R1/DR4 in humans and TRAIL-R2/DR5 in both species ([@bib50]). Other receptors include TRAIL-R3 and TRAIL-R4---considered a decoy receptor because of the lack of or incomplete death domain---and the soluble protein Osteoprotegerin, none of which promote cell death ([@bib10]). TRAIL is a well-established player in anti-tumor immunity, potently clearing TRAIL-R-expressing tumors without affecting normal primary tissue ([@bib51]). Indeed, several reports established that TRAIL is involved in NK cell-mediated rejection of transplanted tumors expressing TRAIL-R ([@bib42], [@bib45]), chemically induced sarcoma ([@bib7]), and liver metastases ([@bib7], [@bib40], [@bib42]) as well as hematological malignancies ([@bib59]).

An important and increasingly recognized function of TRAIL is its involvement in the regulatory function of NK cells ([@bib22]), especially in contexts of virally induced chronic inflammation ([@bib28], [@bib39]). In the well-studied model of mouse cytomegalovirus (MCMV) infection, NK cells can limit the function and antiviral T cell responses via elimination of MCMV-infected dendritic cells ([@bib1]) and CD4^+^ T cells ([@bib38]). Inflammatory cytokines such as IFNs ([@bib42], [@bib43]), interleukin-26 (IL-26) ([@bib31]), and IL-15 and IL-2 ([@bib25]) have been found to induce TRAIL expression on NK cells; however, the intrinsic pathways regulating TRAIL expression have not been defined. Using the NKp46-deficient mouse strain *Ncr1*^*gfp/gfp*^ (designated *Ncr1*^*−/−*^ hereafter), the present study uncovers a link between TRAIL and NKp46, showing that NKp46 is necessary and sufficient for TRAIL surface expression in ILC1s and NK cells.

Results {#sec2}
=======

NKp46 Is Necessary for TRAIL Surface Expression on NK Cells and ILC1s {#sec2.1}
---------------------------------------------------------------------

While characterizing different subsets of liver NK cells in resting NKp46-deficient mice (*Ncr1*^*−/−*^ ) ([@bib41]), we discovered that CD3^−^ NK1.1^+^ NK cells lacked TRAIL surface expression, in contrast with their wild-type (*Ncr1*^*+/+*^) and heterozygote (*Ncr1*^*+/−*^) littermates ([Figures 1](#fig1){ref-type="fig"}A--1C). To distinguish liver ILC1s, also known as resident TRAIL^+^ NK cells, from conventional mature NK cells, we used DX5 (CD49b) and CD49a markers. We observed similar proportions of liver ILC1s (CD49b/DX5^−^ CD49a^+^) and mature NK cells (CD49b/DX5^+^CD49a^−^) in both strains ([Figures 1](#fig1){ref-type="fig"}D and 1E; [@bib41]). ILC1s were further identified as DX5^−^ Eomes^−^ in the livers of *Ncr1*^*+/+*^ mice, where they represented the main population of TRAIL-expressing cells, as expected ([Figures 1](#fig1){ref-type="fig"}F and 1G). However, in the *Ncr1*^*−/−*^ mouse, TRAIL was virtually absent from liver ILC1s that were present at normal frequency ([Figures 1](#fig1){ref-type="fig"}F and 1G). Similarly, TRAIL was absent from small populations of ILC1s detected in the spleen and lymph nodes of *Ncr1*^*−/−*^ mice as well as from mature and immature NK cells present in the lymph nodes ([Figures 1](#fig1){ref-type="fig"}F and 1G). Hence, the absence of TRAIL expression in the *Ncr1*^*−/−*^ mouse is not due to a defect in the differentiation of NK cells and ILC1s but a direct consequence of the lack of NKp46.Figure 1ILC1s Lack TRAIL Expression in NKp46-Deficient Mice(A) Representative flow cytometry plots showing frequencies of T cells (CD3^+^ NK1.1^−^), NKT cells (CD3^+^ NK1.1^+^), and NK cells (CD3^−^ NK1.1^+^) in the livers of naive wild-type mice, *Ncr1*^*−/−*^ mice, or heterozygous *Ncr1*^*+/−*^ mice.(B and C) Representative flow cytometry histograms (B) and average percentage (± SD) (C) of TRAIL^+^ group1 ILCs detected in the livers of *Ncr1*^*+/−*^ and *Ncr1*^*−/−*^ mice.(D and E) Representative flow cytometry plots of TRAIL, CD49b/DX5, and CD49a expression on hepatic group 1 innate lymphoid cells (CD3^−^ NK1.1^+^) from naive *Ncr1*^*+/−*^ and *Ncr1*^*−/−*^ mice (D) and average percentage (± SD) of CD49b/DX5^+^ NK cells (E, left) and CD49a^+^ NK cells (E, right) as described in (D).(F) Representative flow cytometry plots of the gating strategy used to distinguish (CD3^−^ NK1.1^+^) ILC subsets: mature NK cells (CD49b^+^Eomes^+^) from immature NK cells (CD49b^+^Eomes^−^) and ILC1s (CD49b^−^ Eomes^−^) in liver, lymph node (LN), and spleen tissues harvested from *Ncr1*^*+/−*^ and *Ncr1*^*−/−*^ mice.(G) Representative flow cytometry histograms of TRAIL expression on the cell subsets defined in (F).Data are representative of 2--4 experiments, each with 2--5 mice per group. ^∗∗∗∗^p \< 0.0001 (unpaired t test).

NKp46 Positively Regulates TRAIL Induction *In Vivo* {#sec2.2}
----------------------------------------------------

To investigate TRAIL induction *in vivo*, we injected *Ncr1*^+/+^ and *Ncr1*^−/−^ mice with poly(I:C) and α-galactosylceramide (α--GalCer), 2 immunogenic compounds known to upregulate TRAIL on NK cells via induction of proinflammatory cytokines ([@bib42], [@bib46], [@bib48]). NK cells and ILC1s retrieved from the lymph nodes of poly(I:C)-injected *Ncr1*^+/+^ and *Ncr1*^−/−^ mice showed similar expression profiles of the activation marker CD69, indicating comparable activation levels ([Figure 2](#fig2){ref-type="fig"}A). Nonetheless, in the absence of NKp46, mature NK cells and ILC1s analyzed from the lymph nodes of *Ncr1*^−/−^ mice were unable to induce TRAIL post-stimulation with poly(I:C) ([Figures 2](#fig2){ref-type="fig"}B and 2D). We obtained similar results upon α-GalCer stimulation, where splenic NK cells in *Ncr1*^−/−^ mice were unable to induce TRAIL cell surface expression ([Figures 2](#fig2){ref-type="fig"}C and 2E). We have previously demonstrated that NKp46-deficient NK cells produce comparable amounts of IFN-γ upon activation with IL-2 and IL12 + IL-18 and upon triggering of the activating receptors NK1.1, Ly49D, and NKG2D to that produced by wild-type NK cells ([@bib41]). In addition, expression of the IFN-γ receptor (CD119) is equivalent in NK cells from *Ncr1*^−/−^ and *Ncr1*^+/+^ mice ([Figure S1](#mmc1){ref-type="supplementary-material"}). Collectively, these data indicate that the inability of NK cells to induce TRAIL in the absence of NKp46 is not due to a defect in NK cell activation.Figure 2NKp46-Deficient NK Cells and ILC1s Fail to Upregulate TRAIL upon *In Vivo* Activation(A) Representative flow histograms of CD69 expression on ILC1s and mature and immature NK cells isolated from *Ncr1*^*+/−*^ and *Ncr1*^*−/−*^ mice stimulated with poly(I:C) for 24 hr (top) and the CD1d ligand α-galactosylceramide (α-GalCer) for 9 days (bottom).(B and C) Representative flow cytometry plots showing expression of TRAIL and CD49b/Dx5 expression on (CD3^+^ NK1.1^+^) cells isolated from *Ncr1*^*+/−*^ and *Ncr1*^*−/−*^ mice stimulated with poly(I:C) (LN) (B) and α-GalCer (spleen) (C) as described above.(D and E) Bar graph representing the average percentage (± SD) of TRAIL^+^ NK cells (CD3^−^ NK1.1^+^) isolated from *Ncr1*^*+/−*^ and *Ncr1*^*−/−*^ mice left unstimulated (PBS) or stimulated as described above with poly(I:C) (LN) (D) and α-GalCer (spleen) (E).Data are representative of 2--4 experiments, each with 2--5 mice per group. The p values were measured by unpaired t test. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

IL-2 and IL-15 Fail to Upregulate TRAIL on Mature *Ncr1*^−/−^ NK Cells {#sec2.3}
----------------------------------------------------------------------

Mature splenic NK cells in wild-type mice do not express TRAIL unless activated in culture in the presence of IL-2 ([@bib48]) or IL-15 ([@bib25], [@bib58]). To assess the kinetics of TRAIL induction on *in vitro*-activated NK cells, we cultured splenic NK cells isolated from *Ncr1*^+/+^ and *Ncr1*^−/−^ mice for 5 days in the presence of IL-15 or IL-2. A small fraction of NKp46-sufficient NK cells expressed high levels of TRAIL on day 2 that progressively increased over time ([Figures 3](#fig3){ref-type="fig"}A--3C). However, NK cells deficient in NKp46 failed to induce significant levels of cell surface TRAIL after 5 days of culture with IL-15 ([Figures 3](#fig3){ref-type="fig"}A and 3B) or with IL-2 ([Figure 3](#fig3){ref-type="fig"}C). NK cells from *Ncr1*^+/+^ and *Ncr1*^−/−^ mice expressed equivalent levels of the IL-2 receptor α chain (CD25) and the β (CD122) and γ chains (CD132) shared by the IL-2 and IL-15 receptors ([Figure S1](#mmc1){ref-type="supplementary-material"}). Thus, the differences in the induction of TRAIL expression were not the result of differential signaling through these receptors.Figure 3IL-2 and IL-15 Fail to Induce TRAIL Protein Expression at the Membrane of NKp46-Deficient NK Cells(A) Representative flow histograms of TRAIL induction on IL-15-activated splenic NK cells (CD3^−^ NK1.1^+^) isolated from *Ncr1*^*+/−*^ (top) and *Ncr1*^*−/−*^ (bottom) mice (5 day culture in IL-15, 50 ng/mL). The negative control is depicted as fluorescence minus one (FMO).(B and C) Average percentage (± SD) of TRAIL^+^ NK cells generated over 5 days of culture in the presence of IL-15 (50 ng/mL) (n = 3 mice/genotype) (B) and IL-2 (50 U/ml) (n = 3 mouse/genotype) (C). Values represent means ± SD. Statistical significance was measured via unpaired Mann-Whitney test).(D) Mean fluorescence intensity of TRAIL and NKp46 co-expressed on splenic NK cells shown on day 5 for various concentrations of IL-15 as indicated in the plot.The data in (A)--(D) are representative of 4 or more experiments.(E) Representative confocal images obtained by ImageStream analysis of IL-15-activated NK cells isolated from *Ncr1*^*−/−*^*(Ncr1*^*gfp/gfp*^*)* and *Ncr1*^*+/−*^*(Ncr1*^*gfp/+*^*)* mice that express endogenous GFP. Staining with antibodies specific for NK1.1 and TRAIL or isotype phycoerythrin (PE) control is shown, as well as bright-field (BF) images. Zombie dye was used to gate out dead cells. Three cells representative of at least 480 events acquired (GFP^+^ NK cells) per condition are shown and are representative of 3 independent experiments. The scale bar represents 7 μm.(F) Bar graph depicting the relative average expression (± SD) of *Tnfsf10* mRNA in IL15-activated splenic NK cells isolated from *Ncr1*^*+/−*^ and *Ncr1*^*−/−*^ mice (5 days culture in IL-15, 50 ng/mL). Data are a pool of 3 mice per group combined from 1--2 experiments.(G) Western blot analysis of the total TRAIL protein expressed in *Ncr1*^*+/+*^, *Ncr1*^*+/−*^, and *Ncr1*^*−/−*^ NK cells upon activation (5 day culture in IL-2, 1,000 U/mL). Data are representative of 2 independent experiments. Actin was used as a reference.(H) Representative flow histogram of TRAIL intracellular staining or isotype control (shaded gray) of IL-2-activated splenic NK cells isolated from *Ncr1*^*+/−*^ (red line) and *Ncr1*^*−/−*^ (black) mice.Data are representative of 2 independent experiments. See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.

Interestingly, we observed a positive correlation between NKp46 and TRAIL expression in *Ncr1*^+/+^ mice, dependent on the concentration of IL-15 present in the culture. Low levels of IL-15 (10 ng/mL) induced high levels of NKp46 and TRAIL that diminished with increasing concentrations of IL-15 ([Figure 3](#fig3){ref-type="fig"}D).

Because a small fraction of NKp46-deficient NK cells seems to be weakly positive for TRAIL when assessed via flow cytometry (shoulder positivity), we employed ImageStream to visualize TRAIL at the cell membrane, using NK1.1 expression as positive control. [Figure 3](#fig3){ref-type="fig"}E shows that the faint TRAIL staining seen in NKp46-deficient NK cells (bottom) was similar to the signal detected by isotype staining (center) and significantly lower than TRAIL^low^ and TRAIL^hi^ staining in NK cells from wild-type mice (top) ([Figure S2](#mmc1){ref-type="supplementary-material"}). We conclude that TRAIL is mainly absent from NKp46-deficient NK cells, although we cannot totally exclude that a very low amount of TRAIL spontaneously reaches the surface of NKp46-deficient NK cells.

To gain further insight into the stage of TRAIL regulation by NKp46, we quantified the amount of *Tnfsf10* transcripts coding for TRAIL in sorted NK cells cultured in the presence of IL-15 for 5 days. Similar levels of *Tnfsf10* mRNA were detected in NK cells from *Ncr1*^+/+^ and *Ncr1*^−/−^ mice, indicating that NKp46 does not control gene transcription or the stability of *Tnfsf10* mRNA ([Figure 3](#fig3){ref-type="fig"}F). This was further shown in liver ILC1s where equal amounts of *Tnfsf10* transcripts were detected in both strains ([Figure S3](#mmc1){ref-type="supplementary-material"}). Western blotting of TRAIL in activated NK cells revealed that the protein was expressed in the presence or absence of NKp46 ([Figure 3](#fig3){ref-type="fig"}G), which was confirmed by intracellular detection of TRAIL in NKp46-deficient NK cells ([Figure 3](#fig3){ref-type="fig"}H). Collectively, these data show that NKp46 controls TRAIL protein expression at a post-translational level by affecting its trafficking to the membrane.

NKp46 Is Sufficient to Restore TRAIL Surface Expression in *Ncr1*^−/−^ NK Cells {#sec2.4}
-------------------------------------------------------------------------------

To determine whether NKp46 is sufficient to induce TRAIL surface expression, we transduced primary NK cells isolated from *Ncr1*^−/−^ mice with an Ncr1-expressing vector. The reintroduction of NKp46 restored TRAIL expression in NKp46-deficient NK cells ([Figures 4](#fig4){ref-type="fig"}A and 4B). Remarkably, the level of TRAIL and NKp46 expression after transfection positively correlated with the NKp46^low^ NK subset expressing lower levels of TRAIL compared with the NKp46^hi^ subset ([Figure 4](#fig4){ref-type="fig"}B). This result is consistent with those obtained using IL-15-activated NK cells ([Figure 3](#fig3){ref-type="fig"}D). In conclusion, our data show that NKp46 is sufficient to control TRAIL surface expression in a dose-dependent manner.Figure 4Reintroduction of NKp46 in NKp46-Deficient Cells Restores TRAIL Membrane Expression(A) Representative flow plots of NKp46 expression on *Ncr1*^*−/−*^ mice (*gfp* knockin) NK cells transduced with an *Ncr1-*expressing vector or empty vector and identified via expression of endogenous GFP. Co-staining for NKp46 expression is shown on the y axis. Percentages of NK cells showing no, low, or high expression of NKp46 are indicated on each plot.(B) Representative flow histograms of TRAIL expression on NKp46^high^, NKp46^low^, and NKp46^neg.^ NK cells per gating shown in (A).Data are representative of 3 experiments, each with 1--2 mice per group.

Discussion {#sec3}
==========

In this study, we describe an unexpected link between murine NKp46 and the death-inducing ligand TRAIL, proteins that are coexpressed by ILC1s and NK cells. Analysis of the NKp46-deficient mouse revealed that ILC1s and small subsets of immature NK cells lack TRAIL membrane expression at steady state in an otherwise normal immune context ([@bib41]). These data indicate that impaired TRAIL expression in the *Ncr1*^*−/−*^ mouse is caused by the lack of NKp46 and not by developmental defects in the ILC compartment. In addition, in the absence of NKp46, mature NK cells activated *in vitro* and *in vivo* fail to upregulate cell surface TRAIL unless NKp46 is transduced. We demonstrate that NKp46 is necessary for TRAIL surface expression and that this likely involves a cell-intrinsic regulatory mechanism.

This phenotype raises several key questions with regards to the mechanism(s) involved. First, how is NKp46 controlling TRAIL expression? NKp46 likely affects TRAIL trafficking to the membrane because we detected a comparable amount of transcripts encoding TRAIL and cytosolic protein in NKp46-deficient and -sufficient NK cells. Possible mechanisms include a requirement for NKp46 to release TRAIL from cytoplasmic vesicles and/or to act as a chaperone for TRAIL localization to the plasma membrane. Co-localization studies of TRAIL and NKp46 via Förster resonance energy transfer imaging are currently investigating TRAIL trafficking and putative association with NKp46. Second, is NKp46 ligand-induced downstream signaling required for TRAIL cell surface expression in group 1 innate lymphoid cells? If so, does it involve the engagement of NKp46 via membrane and/or intracellular ligands? The transmembrane region of NKp46 is critical for binding the adaptor molecules FcεRIγ and CD3ζ ([@bib54]). Studies examining TRAIL expression in NK cells selectively modified in this region and thus defective in NKp46 signaling will provide critical mechanistic insights. Moreover, the *Noé* mouse is a valuable model that might help address the requirement for NKp46 to bind extracellular ligands because the mouse has impaired NKp46 surface expression ([@bib33]) but retains cytoplasmic NKp46 ([@bib16], [@bib33]). Additional questions arise from the fact that other cell types that do not express NKp46, including monocytes ([@bib12]) and T cells ([@bib23]), can exhibit cell surface TRAIL expression upon infection, findings that imply that NKp46-mediated control of TRAIL may be specific to the ILC compartment.

With regards to the biological relevance of TRAIL regulation by NKp46, both proteins are known players in anti-tumor responses ([@bib26], [@bib40], [@bib51]); hence, the concomitant expression of NKp46 and TRAIL is likely to potentiate NK cell direct killing activity against tumors bearing NKp46 ligands and TRAIL receptors. Also, TRAIL/TRAIL-R is a critical axis of immunoregulation by NK cells upon persistent infection ([@bib38]). The constitutive expression of TRAIL on resident hepatic NK cells and upregulation via inflammatory cytokines likely contribute to maintaining an immunosuppressive environment characteristic of the liver tissue and avoiding hepatitis upon prolonged cytokine exposure. [@bib36] previously demonstrated that TRAIL^+^ NK cells contribute to persistent infection and liver damage by eliminating hepatitis B virus (HBV)-specific CD8^+^ T cells that upregulate TRAIL-R2, thereby becoming susceptible to TRAIL-mediated apoptosis ([@bib36]). Recently, [@bib57] observed a higher frequency of NKp46 in HBV-infected patients with a high viral DNA titer compared with healthy subjects, which correlated with high levels of alanine transaminase (ALT), a hallmark of liver damage ([@bib57]). The authors showed that a subset of NKp46^hi^NKG2A^hi^ NK cells displays an elevated level of TRAIL mRNA and a high cytotoxic potential against activated T cells *in vitro* ([@bib57]). Hence, it is plausible that NKp46 and TRAIL act in concert to target TRAIL-R-expressing immune cells upon persistent inflammation in HBV-infected patients. Similarly, NKp46-deficient mice were used to demonstrate that NK cells can attenuate liver fibrosis via NKp46-mediated killing of hepatic stellate cells (HSCs) that express NKp46 ligands ([@bib19]); TRAIL could potentially be involved in the protective role of NK cells in this model.

NK cells can also participate in tissue damage in the context of persistent inflammation. NK cells contribute to TRAIL-mediated apoptosis of hepatocytes isolated from HBV-infected individuals, suggesting that TRAIL^+^ NK cells have the potential to promote liver damage ([@bib11]). Similarly, NK cells have been involved in the pathogenesis of autoimmune diseases such as type 1 diabetes. There is a high frequency of activated NKp46^+^ NK cells in diabetic patients ([@bib52]), and NKp46 ligands are detected on human and mouse pancreatic β cells, with the ability to induce NKp46-mediated NK cell degranulation ([@bib18]). Compared with the NKp46-sufficient mouse, NKp46-deficient mice developed low-dose-of-streptozotocin (LDST)-induced type 1 (T1) diabetes at a lower frequency and displayed lower blood glucose levels, demonstrating the role of NKp46 in the development of diabetes ([@bib18]). TRAIL could be involved in the NKp46-mediated NK cell response in this model. Indeed, it is known that the normal human pancreas exhibits a high amount of TRAIL-R under chronic inflammatory conditions such as chronic pancreatitis ([@bib21]); hence, NK cells could be deleterious via both NKp46/NKp46 ligands and TRAIL/TRAIL-R interactions.

In conclusion, several phenotypes based on studies of the NKp46-deficient mouse may actually arise because of the concomitant lack of TRAIL and NKp46 expression. The relationship between NKp46 and TRAIL described here should be taken into consideration when reflecting on past studies of the *Ncr1*^*−/−*^ mouse and on future studies addressing NKp46 and TRAIL functions.

Experimental Procedures {#sec4}
=======================

Further details and an outline of resources used in this work can be found in the [Supplemental Information](#app2){ref-type="sec"}.

Animals {#sec4.1}
-------

*Ncr1*^*gfp/gfp*^ mice (RRID:IMSR_JAX:022739), kindly provided by Prof. Ofer Mandelboim ([@bib14]), were bred and maintained in the animal facility at Imperial College London in a specific pathogen-free environment. Work was carried out in compliance with the British Home Office Animals Scientific Procedures Act 1986 (PPL70/7129).

NK Cell Isolation, Activation, and Transduction {#sec4.2}
-----------------------------------------------

NK cells were activated *in vitro* in complete RPMI medium supplemented with IL-2 or IL-15 as indicated in the figure legends. 2 μg of α-GalCer (intraperitoneally \[i.p.\]) or 100 μg of poly(I:C) was used to activate NK cells *in vivo.* 293T cells were transfected with the vesicular stomatitis virus G protein (VSV-G)-pseudotyped lentiviral vector SIN18-RhMLV-Cppt-2E ([@bib47]) containing *GFP* or *Ncr1* using TransIT-293 (Mirus). NK cells that had been cultured for 3 days in 1,000 U/mL IL-2 were transduced with viral particles containing supernatant and assessed for TRAIL and NKp46 expression by flow cytometry.

RNA Isolation and Real-Time qPCR {#sec4.3}
--------------------------------

Reverse-transcribed cDNA was amplified using the TaqMan PreAmp Master Mix Kit prior to real-time qPCR (TaqMan system, Applied Biosystems). All values were normalized to *Gapdh* expression.

Western Blotting {#sec4.4}
----------------

Total cell lysate transferred to a polyvinylidene fluoride (PVDF) membrane was immunoblotted with either anti-TRAIL or anti-actin antibodies prior blot analysis (Image Lab software, Bio-Rad).

ImageStream {#sec4.5}
-----------

Primary splenocytes were stained for the indicated markers and analyzed on ImageStreamX Mark II (Amnis, USA) and analyzed using IDEAS software.

Statistical Analyses {#sec4.6}
--------------------

Two-tailed unpaired Student's t test and Mann-Whitney tests were applied (as indicated in the figure legends) when appropriate (GraphPad). Differences at p ≤ 0.05 were considered significant: ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, ^∗∗∗^p ≤ 0.001, ^∗∗∗∗^p ≤ 0.0001.

Supplemental Information {#app2}
========================

Document S1. STAR Methods and Figures S1--S3Document S2. Article plus Supplemental Information
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